Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy RARE?
Source: PRnewswire
- Class Action Initiation: Robbins Geller law firm announces a class action lawsuit against Ultragenyx Pharmaceutical, representing stock purchasers from August 3, 2023, to December 26, 2025, alleging violations of the Securities Exchange Act by top executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors by failing to disclose risks associated with the Phase III Orbit study, where patients did not achieve a statistically significant reduction in annualized fracture rates, impacting stock price perception.
- Stock Price Plunge: Following the announcement on July 9, 2025, and December 29, 2025, regarding the failure to achieve statistical significance in study results, Ultragenyx's stock fell over 25% and 42% respectively, indicating a severe loss of investor confidence.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act, any investor who purchased Ultragenyx stock during the class period can seek to be appointed as lead plaintiff, ensuring their rights are represented in the lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.460
Low
35.00
Averages
61.65
High
120.00
Current: 21.460
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is facing a class action lawsuit for securities fraud covering the period from August 3, 2023, to December 26, 2025, with investors required to file for lead plaintiff status by April 6, 2026, to protect their rights.
- Allegation Details: The lawsuit alleges that the company made significant false statements regarding its drug setrusumab, failing to disclose that its Phase III Orbit study did not achieve statistical significance, misleading investors about the company's prospects.
- Stock Price Impact: Following the announcement on December 29, 2025, that its clinical trials failed to meet primary endpoints, Ultragenyx's stock plummeted over 42%, from $34.19 per share on December 26, 2025, to $19.72, severely undermining investor confidence.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation or may choose to remain an absent class member while still participating in the class action for potential recovery.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Ultragenyx Pharmaceutical stock between August 3, 2023, and December 26, 2025, can seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934 by the company and its executives.
- Stock Price Plunge: Following the July 9, 2025 announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock fell over 25%; on December 29, 2025, the company revealed further study failures, causing an additional drop of over 42% in stock price.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors by failing to disclose risks associated with patient fracture rates, creating a false impression of product efficacy, which significantly impacted investor decisions and trust.
- Law Firm Credentials: Robbins Geller is one of the world's leading class action firms, recovering over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years, underscoring its significant expertise in securities fraud litigation.
See More
Ultragenyx Pharmaceutical Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI), leading to inflated stock purchases and subsequent investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, as many firms issuing notices lack actual litigation experience and may merely act as intermediaries, thus emphasizing the importance of choosing a firm with a proven success record to protect their interests.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical for violations of securities laws, concerning securities purchases between August 3, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on Osteogenesis Imperfecta patients, leading to an overly optimistic outlook that misled investors and affected market confidence.
- Clinical Trial Failure: The Phase III ORBIT study revealed that Ultragenyx failed to achieve a statistically significant reduction in annualized fracture rate, highlighting significant errors in the company's drug efficacy claims and exacerbating investor losses.
- Legal Consequences: As the market learned the truth about Ultragenyx, investors suffered damages, prompting the Schall Law Firm, which specializes in securities class actions, to assist affected shareholders in recovering their losses.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Claims
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, covering the period from August 3, 2023, to December 26, 2025, indicating that investors may face significant losses.
- Legal Rights Reminder: The firm emphasizes that investors who purchased or acquired Ultragenyx securities during this timeframe should contact attorneys promptly to discuss their legal rights, highlighting the importance of protecting investor interests.
- Class Action Deadline: Investors should be aware that the deadline to seek the role of lead plaintiff in the federal securities class action is April 6, 2026, underscoring the urgency for timely action to safeguard their interests.
- Contact Information Provided: Securities Litigation Partner Josh Wilson has made direct contact numbers available, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) for further information and assistance.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit.
- Legal Allegations: Ultragenyx and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to significant investor losses.
- Stock Price Plunge: Following the announcement on December 26, 2025, that setrusumab (UX143) failed to show significant efficacy in clinical trials, Ultragenyx's stock price plummeted approximately 42%, from $34.19 to $19.72, severely impacting the company's market capitalization.
- Case Information: The lawsuit is titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097, and investors can access further legal support and information through ClaimsFiler.
See More
Ultragenyx Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is facing a class action lawsuit for securities fraud covering the period from August 3, 2023, to December 26, 2025, with investors required to file for lead plaintiff status by April 6, 2026, to protect their rights.
- Allegation Details: The lawsuit alleges that the company made significant false statements regarding its drug setrusumab, failing to disclose that its Phase III Orbit study did not achieve statistical significance, misleading investors about the company's prospects.
- Stock Price Impact: Following the announcement on December 29, 2025, that its clinical trials failed to meet primary endpoints, Ultragenyx's stock plummeted over 42%, from $34.19 per share on December 26, 2025, to $19.72, severely undermining investor confidence.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation or may choose to remain an absent class member while still participating in the class action for potential recovery.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Ultragenyx Pharmaceutical stock between August 3, 2023, and December 26, 2025, can seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934 by the company and its executives.
- Stock Price Plunge: Following the July 9, 2025 announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock fell over 25%; on December 29, 2025, the company revealed further study failures, causing an additional drop of over 42% in stock price.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors by failing to disclose risks associated with patient fracture rates, creating a false impression of product efficacy, which significantly impacted investor decisions and trust.
- Law Firm Credentials: Robbins Geller is one of the world's leading class action firms, recovering over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years, underscoring its significant expertise in securities fraud litigation.
See More
Ultragenyx Pharmaceutical Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI), leading to inflated stock purchases and subsequent investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, as many firms issuing notices lack actual litigation experience and may merely act as intermediaries, thus emphasizing the importance of choosing a firm with a proven success record to protect their interests.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical for violations of securities laws, concerning securities purchases between August 3, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on Osteogenesis Imperfecta patients, leading to an overly optimistic outlook that misled investors and affected market confidence.
- Clinical Trial Failure: The Phase III ORBIT study revealed that Ultragenyx failed to achieve a statistically significant reduction in annualized fracture rate, highlighting significant errors in the company's drug efficacy claims and exacerbating investor losses.
- Legal Consequences: As the market learned the truth about Ultragenyx, investors suffered damages, prompting the Schall Law Firm, which specializes in securities class actions, to assist affected shareholders in recovering their losses.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Claims
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, covering the period from August 3, 2023, to December 26, 2025, indicating that investors may face significant losses.
- Legal Rights Reminder: The firm emphasizes that investors who purchased or acquired Ultragenyx securities during this timeframe should contact attorneys promptly to discuss their legal rights, highlighting the importance of protecting investor interests.
- Class Action Deadline: Investors should be aware that the deadline to seek the role of lead plaintiff in the federal securities class action is April 6, 2026, underscoring the urgency for timely action to safeguard their interests.
- Contact Information Provided: Securities Litigation Partner Josh Wilson has made direct contact numbers available, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) for further information and assistance.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit.
- Legal Allegations: Ultragenyx and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to significant investor losses.
- Stock Price Plunge: Following the announcement on December 26, 2025, that setrusumab (UX143) failed to show significant efficacy in clinical trials, Ultragenyx's stock price plummeted approximately 42%, from $34.19 to $19.72, severely impacting the company's market capitalization.
- Case Information: The lawsuit is titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097, and investors can access further legal support and information through ClaimsFiler.
See More
